Condition: Squamous Cell Carcinoma of Head and Neck · Sponsor: University of Arkansas
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
This description comes directly from the study's public registry record.
Madison Trujillo · 501-686-8274 · MTrujillo@uams.edu
Aaron Holley · 501-686-8274 · jaholley@uams.edu
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group, PA | Fayetteville, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Highlands Oncology Group, PA | Rogers, Arkansas, United States | Recruiting |
| Highlands Oncology Group, PA | Springdale, Arkansas, United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Health | Mineola, New York, United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Health | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05952934